Los Angeles Capital Management LLC Acquires Shares of 143,464 Bioventus Inc. (NYSE:BVS)

Los Angeles Capital Management LLC bought a new position in shares of Bioventus Inc. (NYSE:BVS - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 143,464 shares of the company's stock, valued at approximately $1,714,000. Los Angeles Capital Management LLC owned 0.18% of Bioventus as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of BVS. Covestor Ltd acquired a new stake in shares of Bioventus during the third quarter worth $69,000. Principal Financial Group Inc. bought a new position in Bioventus during the 3rd quarter worth about $210,000. Olympiad Research LP acquired a new stake in shares of Bioventus in the 3rd quarter valued at about $251,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Bioventus in the third quarter valued at about $286,000. Finally, CWM LLC acquired a new position in shares of Bioventus during the third quarter worth about $89,000. Institutional investors own 62.94% of the company's stock.

Bioventus Stock Down 0.3 %

Shares of NYSE:BVS traded down $0.03 during midday trading on Thursday, reaching $11.13. The company had a trading volume of 317,919 shares, compared to its average volume of 401,098. The business's 50 day moving average price is $11.90 and its 200 day moving average price is $8.60. Bioventus Inc. has a 1-year low of $3.64 and a 1-year high of $14.38. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The stock has a market cap of $901.20 million, a PE ratio of -18.29 and a beta of 0.88.

Bioventus (NYSE:BVS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share for the quarter, hitting the consensus estimate of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The firm had revenue of $138.96 million for the quarter, compared to analyst estimates of $132.57 million. During the same quarter in the previous year, the firm earned $0.05 EPS. Research analysts forecast that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

Insider Buying and Selling at Bioventus

In other Bioventus news, Director John A. Bartholdson acquired 25,500 shares of the company's stock in a transaction on Monday, August 19th. The shares were purchased at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the purchase, the director now directly owns 6,939,357 shares of the company's stock, valued at approximately $59,331,502.35. This represents a 0.37 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 32.90% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Craig Hallum lifted their target price on Bioventus from $12.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, September 27th. Canaccord Genuity Group lifted their price objective on shares of Bioventus from $12.00 to $15.00 and gave the company a "buy" rating in a report on Wednesday, November 6th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.